Anika Therapeutics (ANIK) is a leader in tissue protection products for human joints, and the company is gaining market share. It has a new product in the FDA's approval process and is already selling in Europe.

Management is lowering costs with manufacturing consolidation, and we believe that they have a number of exciting product development programs. We've initiated coverage on Anika with a BUY rating.

Here are some highlights of the company:

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not necessarily represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer.